Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on translating cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases. The company has significantly reduced its cost base through operational restructuring, including terminating its Worcester cell processing lease and selling equipment to AbbVie. While its lean operating model has dramatically narrowed its net losses, Mustang remains pre-revenue and fully dependent on external equity financing. Given the lack of near-term clinical catalysts, Nasdaq listing compliance risks, and funding constraints under 'baby shelf' rules, a Hold recommendation is warranted until clinical progress or strategic partnerships materialize.